[Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program]
Tremblay E
Record ID 32015000083
French
Authors' objectives:
The objectives of this study were to describe new users of alendronate, risedronate, denosumab or zoledronic acid and to assess the persistence rate and the level of compliance with these pharmacological therapies as well as with concomitantly administered calcium and vitamin D supplements.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/INESSS_Portrait_usage_ost%C3%A9oporose.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Bone Density Conservation Agents
- Canada
- Diphosphonates
- Treatment Outcome
- Medication Adherence
- Medication Therapy Management
- Osteoporosis
- Antibodies, Monoclonal, Humanized
- Middle Aged
- Cost-Benefit Analysis
- Imidazoles
Contact
Organisation Name:
Institut national d'excellence en sante et en services sociaux
Contact Address:
L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name:
demande@inesss.qc.ca
Contact Email:
demande@inesss.qc.ca
Copyright:
©Gouvernement du Québec/Institut national d'excellence en santé et en services sociaux
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.